Vinay Prasad Returns to FDA After Being Ousted
By I. Edwards HealthDay Reporter

MONDAY, Aug. 11, 2025 — The U.S. Food and Drug Administration (FDA)’s top vaccine regulator is returning to his post less than two weeks after the White House had him ousted.
Dr. Vinay Prasad will again head the FDA’s Center for Biologics Evaluation and Research, which oversees vaccines and complex treatments for serious diseases, the U.S. Department of Health and Human Services (HHS) confirmed.
HHS spokesperson Andrew Nixon said Prasad is resuming his role "at the FDA’s request," according to The Washington Post.
"Neither the White House nor HHS will allow the fake news media to distract from the critical work the FDA is carrying out under the Trump administration," Nixon added in a statement.
Prasad, a hematologist-oncologist, joined the Trump administration as a senior health official after publicly criticizing the government’s response to the COVID-19 pandemic.
On July 29, he was removed from his role after some conservative figures such as far-right activist and conspiracy theorist Laura Loomer criticized his approach to drug approvals and his past political views.
However, a White House review found the complaints to be disingenuous, according to two people familiar with the situation.
White House spokesperson Kush Desai said it was "not only appropriate, but critical for the Administration to recruit the most qualified and experienced staffers who are totally aligned with President Trump’s agenda to 'Make America Great Again'."
The reversal followed FDA Commissioner Dr. Marty Makary advocating for Prasad’s return.
“The idea that he was pushed out by anybody is simply untrue,” Makary said at a news conference. “He saw some media headlines and didn’t want to be a distraction. We have encouraged him to reconsider, and we’re still doing that.”
In a post on X, Loomer criticized the decision, calling it an “egregious personnel decision,” and vowed to increase her investigations into HHS and FDA officials.
It is unclear whether Prasad will also return to his additional former role as the FDA’s chief medical and scientific officer.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-08-12 00:00
Read more

- Apnimed Reports Positive Topline Results from Second Phase 3 Trial of AD109, Reinforcing Potential of First Oral Pill for Obstructive Sleep Apnea
- Loneliness Of Widowhood Isn't Diminished By Presence Of Adult Children, Study Says
- Spritam (levetiracetam) Tablets for Oral Suspension Approved by FDA for Nasogastric and Gastrostomy Tube Administration
- EPA Moves to Cancel Key Climate Regulations That Limit Pollution
- Few Schools Screen Students For Depression, Anxiety
- Antiseizure Meds With Known or Uncertain Risks Continue to Be Prescribed in Pregnancy
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions